Clinical trial · Observational
Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer
NCT06326216CI-TRIAL-00109302active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to determine whether levels of prostate cancer derived extracellular vesicles from blood and urine specimens correlate with response to primary local treatment (surgery) in prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Observational (Cohort I)
- description
- Prostate cancer patients undergo blood and urine sample collection on study. Patients' medical records are also reviewed.
- interventionNames
- Other: Non-Interventional Study
- label
- Observational (Cohort III)
- description
- Female urology clinic patients and female volunteers undergo blood and urine sample collection on study.
- interventionNames
- Other: Non-Interventional Study
- label
- Observational (Cohort II)
- description
- Prostate cancer patients undergo blood and urine sample collection throughout the study. Patients' medical records are also reviewed.
Primary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* PROSTATE CANCER PATIENTS:
* Age 18+
* Able to give informed consent
* Patients with prostate cancer
* Patients treated with primary prostatectomy
* The focus will be on high-risk patients with at least one of either criterion:
* PSA \>= 20 ng/ml
* AND/OR Gleason \>= 8
* AND/OR clinical stage \>= T3
* FEMALE CONTROL PATIENTS:
* Age 18+
* Able to give informed consent
Exclusion Criteria:
* PROSTATE CANCER PATIENTS:
* Unable or unwilling to provide informed consent
* Metastatic prostate cancer - defined evidence of metastatic disease on pre-procedural testing
* FEMALE CONTROL PATIENTS:
* Unable or unwilling to provide informed consentReferences
Publications (0)
Data not yet available
No reference posted for this study.